Pharvaris' latest phase 3 win builds case for HAE drug with FDA verdict pending

Pharvaris’ deucrictibant has tasted success in a second phase 3 study, strengthening the case for the therapy to treat hereditary angioedema patients as the Swiss biotech awaits an FDA approval decision.